相似文献
1
From Repurposing to Refinement: Optimizing Levofloxacin for Treatment of Multidrug-Resistant Tuberculosis.
Am J Respir Crit Care Med. 2025 Jul;211(7):1126-1127. doi: 10.1164/rccm.202503-0550ED.
2
Effectiveness and safety of tuberculosis preventive treatment for contacts of patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis.
Clin Microbiol Infect. 2024 Feb;30(2):189-196. doi: 10.1016/j.cmi.2023.09.015. Epub 2023 Sep 22.
3
Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial.
Am J Respir Crit Care Med. 2025 Jul;211(7):1277-1287. doi: 10.1164/rccm.202407-1354OC.
4
Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam.
N Engl J Med. 2024 Dec 19;391(24):2304-2314. doi: 10.1056/NEJMoa2314325.
5
Fluoroquinolones for treating tuberculosis.
Cochrane Database Syst Rev. 2008 Jan 23(1):CD004795. doi: 10.1002/14651858.CD004795.pub3.
6
Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
J Antimicrob Chemother. 2010 Aug;65(8):1551-61. doi: 10.1093/jac/dkq202. Epub 2010 Jun 11.
7
Comprehensive evaluation of the MeltPro MTB/PZA assay for prediction of pyrazinamide resistance in multidrug-resistant tuberculosis.
Microbiol Spectr. 2025 Jul;13(7):e0274524. doi: 10.1128/spectrum.02745-24. Epub 2025 May 22.
8
Fluoroquinolones for treating tuberculosis.
Cochrane Database Syst Rev. 2005 Jul 20(3):CD004795. doi: 10.1002/14651858.CD004795.pub2.
9
Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs.
Br Med Bull. 2016 Jun;118(1):138-48. doi: 10.1093/bmb/ldw019. Epub 2016 May 5.
10
Delayed culture conversion predicts poor outcomes for isoniazid mono-resistant TB in Uganda: a retrospective cross-sectional study from 2017- 2022.
BMC Infect Dis. 2025 Jul 1;25(1):821. doi: 10.1186/s12879-025-11218-5.
本文引用的文献
1
Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial.
Am J Respir Crit Care Med. 2025 Jul;211(7):1277-1287. doi: 10.1164/rccm.202407-1354OC.
2
The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation.
Int J Antimicrob Agents. 2023 Oct;62(4):106939. doi: 10.1016/j.ijantimicag.2023.106939. Epub 2023 Jul 29.
3
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.
4
Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis.
Clin Infect Dis. 2017 Sep 1;65(5):772-778. doi: 10.1093/cid/cix422.
5
Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes.
Ann Am Thorac Soc. 2016 Mar;13(3):364-70. doi: 10.1513/AnnalsATS.201510-690BC.
6
A four-month gatifloxacin-containing regimen for treating tuberculosis.
N Engl J Med. 2014 Oct 23;371(17):1588-98. doi: 10.1056/NEJMoa1315817.
7
Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.
Am J Respir Crit Care Med. 2013 Oct 1;188(7):858-64. doi: 10.1164/rccm.201303-0604OC.
8
Rising to the challenge: new therapies for tuberculosis.
Trends Microbiol. 2013 Sep;21(9):493-501. doi: 10.1016/j.tim.2013.05.002. Epub 2013 Jun 11.
9
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
Am J Respir Crit Care Med. 2013 Jul 1;188(1):97-102. doi: 10.1164/rccm.201212-2328OC.
10
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.
Eur Respir J. 2013 Jul;42(1):156-68. doi: 10.1183/09031936.00134712. Epub 2012 Oct 25.
Zotero 插件